Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.isci.2020.101425 http://scihub22266oqcxt.onion/10.1016/j.isci.2020.101425 32818905!7452173!32818905     free     free     free       iScience 2020 ; 23 (9): 101425 Nephropedia Template TP {{tp|p=32818905|t=2020. ACE2, Metformin, and COVID-19 |pdf=|usr=}}{{32818905}} gab.com Text ACE2, Metformin, and COVID-19 JO: iScience http://www.kidney.de/pget.php?&tw=1&pmid=32818905 #FOAvip COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available. Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19. ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems. Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury. Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently. Metformin is a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression. Twit Text FOAVip ACE2, Metformin, and COVID-19 ????iScience http://www.kidney.de/pget.php?&tw=1&pmid=32818905 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32818905 #FOAvip English Wikipedia <ref>{{Cite pmid|32818905}}</ref> ACE2, Metformin, and COVID-19 #MMPMID32818905 Malhotra A; Hepokoski M; McCowen KC; Y-J Shyy J iScience 2020[Jul]; 23 (9): 101425 PMID32818905show ga COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available. Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19. ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems. Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury. Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently. Metformin is a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression. äACE2, Metformin, and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing